12 results on '"Giacomelli, Andrea"'
Search Results
2. Management of enzyme de-induction in a woman with HIV on methadone maintenance switched from nevirapine- to bictegravir-based antiretroviral regimen.
- Author
-
Cattaneo, Dario, Giacomelli, Andrea, Casalini, Giacomo, Ridolfo, Anna Lisa, and Gervasoni, Cristina
- Subjects
- *
COMBINATION drug therapy , *SUBSTANCE abuse , *METHADONE hydrochloride , *ANTIRETROVIRAL agents , *DRUG therapy , *ENZYMES , *HIV infections , *NEVIRAPINE , *POLYPHARMACY , *TREATMENT effectiveness , *GENERIC drug substitution - Abstract
The article offers information on the management of enzyme de-induction in a woman with HIV who was switched from a nevirapine- to bictegravir-based antiretroviral regimen. Topics include the challenges of methadone maintenance in HIV patients, drug interactions between antiretroviral medications and methadone, and the importance of monitoring and managing enzyme de-induction during antiretroviral regimen switches.
- Published
- 2024
- Full Text
- View/download PDF
3. Breakthrough Acute HIV Infections among Pre-Exposure Prophylaxis Users with High Adherence: A Narrative Review.
- Author
-
Moschese, Davide, Lazzarin, Samuel, Colombo, Martina Laura, Caruso, Francesco, Giacomelli, Andrea, Antinori, Spinello, and Gori, Andrea
- Abstract
Pre-exposure prophylaxis (PrEP) is a pivotal intervention among HIV prevention strategies. We aimed to narratively revise the topic of HIV acute infection in the setting of PrEP exposure with a focus on diagnostic options, clinical features, and future PrEP perspectives, with a particular focus on users with high adherence to PrEP. We searched the main databases (PubMed, Embase, and Scopus) with the keywords "PrEP" or "Pre-Exposure Prophylaxis" and "HIV" or "PLWH" and "breakthrough" or "acute infection" or "primary infection". We included all randomized clinical trials and non-experimental studies (both case reports and observational studies) ever published. In the present narrative review, we revise the diagnostic challenges related to HIV diagnosis in the setting of PrEP and the clinical characteristics and symptoms of breakthrough infections. We discuss the management of acute HIV infection during PrEP and the new challenges that arise from the use of long-acting drugs for PrEP. Our review underlines that although extremely rare, HIV seroconversions are still possible during PrEP, even in a context of high adherence. Efforts to promptly identify these events must be included in the PrEP follow-up in order to minimize the chance of overlooked HIV breakthrough infections and thus exposure to suboptimal concentrations of antiretrovirals. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Prognostic Significance of NLR and PLR in COVID-19: A Multi-Cohort Validation Study.
- Author
-
Colaneri, Marta, Genovese, Camilla, Fassio, Federico, Canuti, Marta, Giacomelli, Andrea, Ridolfo, Anna Lisa, Asperges, Erika, Albi, Giuseppe, Bruno, Raffaele, Antinori, Spinello, Muscatello, Antonio, Mariani, Bianca, Canetta, Ciro, Blasi, Francesco, Bandera, Alessandra, and Gori, Andrea
- Subjects
- *
CONTINUOUS positive airway pressure , *COVID-19 , *PLATELET lymphocyte ratio , *NEUTROPHIL lymphocyte ratio - Abstract
Introduction: Recent studies have highlighted the prognostic value of easily accessible inflammatory markers, neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR) for predicting severe outcomes in patients affected by Coronavirus disease 2019 (COVID-19). Our study validates NLR and PLR cut-off values from a prior cohort at IRCCS Policlinico San Matteo (OSM) of Pavia, Italy, across two new cohorts from different hospitals. This aims to enhance the generalizability of these prognostic indicators. Methods: In this retrospective cohort study, conducted at Milan's Ospedale Luigi Sacco (OLS) and IRCCS Ospedale Maggiore Policlinico (OMP) hospitals, we assess the predictive capacity of NLR and PLR for three main outcomes—non-invasive ventilation (NIV) or continuous positive airway pressure (CPAP) usage, invasive ventilation (IV), and death—in patients with COVID-19 at admission. For each outcome, sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were computed separately for male and female cohorts. Distinct NLR and PLR cut-off values were used for men (7.00, 7.29, 7.00 for NLR; 239.22, 248.00, 250.39 for PLR) and women (6.36, 7.00, 6.28 for NLR; 233.00, 246.45, 241.54 for PLR), retrieved from the first cohort at OSM. Results: A total of 3599 patients were included in our study, 1842 from OLS and 1757 from OMP. OLS and OMP sensitivity values for both NLR and PLR (NLR: 24–67%, PLR: 40–64%) were inferior to specificity values (NLR: 64–76%, PLR: 55–72%). Additionally, PPVs generally remained lower (< 63%), while NPVs consistently surpassed 68% for PLR and 72% for NLR. Finally, both PLR and NLR exhibited consistently higher NPVs for more severe outcomes (> 82%) compared to NPVs for CPAP/NIV. Conclusions: Consistent findings across diverse patient populations validate the reliability and applicability of NLR and PLR cut-off values. High NPVs emphasize their role in identifying individuals less likely to experience severe outcomes. These markers not only aid in risk stratification but also guide resource allocation in emergencies or limited-resource situations. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. Rilpivirine and cabotegravir trough concentrations in people with HIV on long-term treatment with long-acting injectable antiretrovirals.
- Author
-
Cossu, Maria Vittoria, Cattaneo, Dario, Moschese, Davide, Giacomelli, Andrea, Soloperto, Sara, D'Avolio, Antonio, Antinori, Spinello, Gori, Andrea, Rizzardini, Giuliano, and Gervasoni, Cristina
- Subjects
- *
HIV-positive persons , *BODY mass index , *VIRAL load , *BODY weight , *ATAZANAVIR , *VIRAL replication , *ANTIRETROVIRAL agents - Abstract
Objective Large inter-individual variability in the pharmacokinetics of rilpivirine and cabotegravir has been reported in the first weeks after starting long-acting injectable (LAI) therapy. Here, we assessed the distribution of rilpivirine and cabotegravir trough concentrations in people with HIV (PWH) on long-term LAI treatment. Methods Adult PWH treated with LAI for at least 32 weeks with an assessment of drug plasma trough concentrations were considered. The proportion of rilpivirine and cabotegravir plasma trough concentrations below four-times the protein-adjusted concentrations required for 90% inhibition of viral replication (4×PA-IC90) was estimated. Results Sixty-seven PWH were identified. LAI treatment duration was 216 ± 80 weeks (range 32–320 weeks). Cabotegravir concentrations were associated with lower inter-individual variability compared with rilpivirine (45% versus 84%; P < 0.05). No differences were found in rilpivirine (160 ± 118 versus 189 ± 81 ng/mL; P = 0.430) and cabotegravir (1758 ± 807 versus 1969 ± 802 ng/mL; P = 0.416) trough concentrations in males (n = 55) versus females (n = 12). A non-significant trend for lower cabotegravir concentrations was found in PWH with a body mass index >30 kg/m2 (n = 9) versus non-obese participants (1916 ± 905 versus 1606 ± 576 ng/mL; P = 0.131). Three out of the 67 PWH had at least one drug concentration <4×PA-IC90: 100% of PWH had undetectable HIV viral load. Conclusions At steady state, optimal systemic exposure of cabotegravir and rilpivirine was found in most PWH; cabotegravir trough concentrations were associated with lower inter-individual variability compared with rilpivirine. The study was not powered to assess the contribution of sex and/or body weight on LAI exposure due to the small number of females and obese PWH included. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
6. Detection and typization of HPV genotypes in subjects with oral and upper respiratory tract lesions, Milan, Italy.
- Author
-
Rizzo, Alberto, Salari, Federica, Eplite, Angelo, Giacomelli, Andrea, Moschese, Davide, Dalu, Davide, Cossu, Maria Vittoria, Lorusso, Rosaria, Pozza, Giacomo, Morelli, Loriana, Fasola, Cinzia, Tonielli, Claudia, Fusetti, Chiara, De Cristofaro, Valeria, Gori, Andrea, Lombardi, Alessandra, Rizzardini, Giuliano, Gismondo, Maria Rita, and Antinori, Spinello
- Subjects
- *
HUMAN papillomavirus , *GENITAL warts , *HEAD & neck cancer , *RESPIRATORY infections , *ORAL sex , *TONGUE cancer - Abstract
Oral human papillomavirus (HPV) is common among healthy individuals but causes and implications of persistent infections are under evaluation in the pathogenesis of head and neck neoplasms. This was a retrospective study evaluating the prevalence of high-risk (HR), probable HR and low-risk (LR) HPV types in patients reporting signs/symptoms of oral and upper respiratory tract lesions. Individuals attending between 2019 and 2022 a University Hospital in Milan, Italy, with risk factors for HPV (unprotected oral sex and/or previous documentation of HPV infection in oral and upper respiratory tract and/or another anatomical site) were included. Fourteen out of 110 (12.7%) individuals tested positive for HPV DNA. The prevalence of HR-HPV and LR-HPV was 3.6% (4/110) and 9.1% (10/110), respectively. No probable/possible HR-HPV was detected. Specifically, 10/110 (9.1%) were diagnosed with 1 LR-HPV genotype, 3/110 (2.7%) were infected with 1 HR-HPV and 1/110 had 3 concomitant HR-HPV types. HPV 16 (2.7%, 3/110) and 6 (4.5%, 5/110) were the most common HR and LR types, respectively. One patient positive for HPV 16, 33 and 35 was diagnosed with cancer at the base of the tongue. Two individuals among those who tested positive for HPV DNA reported previous HPV vaccination. Our data, in line with observations from previous prevalence studies, support the potential role of HPV in head and neck neoplasms. HPV DNA testing should be performed in patients presenting lesions in oral/respiratory tracts and risk factors for HPV. Improvement in HPV vaccination coverage is warranted. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. Sleep disorders during the COVID‐19 pandemic: Results from the second phase of web‐based EPICOVID19 study.
- Author
-
Trevisan, Caterina, De Vincentis, Antonio, Noale, Marianna, Maggi, Stefania, Antonelli Incalzi, Raffaele, Pedone, Claudio, Prinelli, Federica, Giacomelli, Andrea, Fortunato, Loredana, Molinaro, Sabrina, Cori, Liliana, and Adorni, Fulvio
- Abstract
The COVID‐19 pandemic has induced significant impairments, including sleep disturbances. The present study aimed to explore the impact of fear in relation to stress on sleep disorders among Italian adults and older participants in the second phase of the EPICOVID19 web‐based survey (January‐February 2021). Sleep disturbances during the pandemic were evaluated using the Jenkins Sleep Scale, perceived stress through the 10‐item Perceived Stress Scale and fear of contagion and about economic and job situation with four ad hoc items. The strength of the pathways between stress, sleep disturbances and fear was explored using structural equation modelling, hypothesising that stress was related to sleep disturbances and that fear was associated with both stress and sleep problems. Out of 41,473 participants (74.7% women; mean age 49.7 ± 13.1 years), 8.1% reported sleep disturbances and were more frequently women, employed in a work category at risk of infection or unemployed, and showed higher deprivation scores. Considering an a priori hypotheses model defining sleep and stress scores as endogenous variables and fear as an exogenous variable, we found that fear was associated with sleep problems and stress, and stress was associated with sleep problems; almost half of the total impact of fear on sleep quality was mediated by stress. The impact of stress on sleep quality was more evident in the younger age group, among individuals with a lower socioeconomic status and healthcare workers. Fear related to COVID‐19 seem to be associated with sleep disturbances directly and indirectly through stress. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
8. Treatment Experienced People Living With HIV switching to DOR/3TC/TDF in Outpatient Setting: Real-World Data on Tolerability and Cost Savings From an Italian Multicenter Cohort.
- Author
-
Iannone, Valentina, Ciccullo, Arturo, Moschese, Davide, Giacomelli, Andrea, Fabbiani, Massimiliano, Lagi, Filippo, Papalini, Chiara, De Vito, Andrea, Cossu, Maria Vittoria, Di Giambenedetto, Simona, and Borghetti, Alberto
- Published
- 2024
- Full Text
- View/download PDF
9. Risk of virological failure after drug burden reduction in people with 4-class drug-resistant HIV on virological suppression: A retrospective cohort analysis of data from the PRESTIGIO Registry.
- Author
-
Clemente, Tommaso, Diotallevi, Sara, Lolatto, Riccardo, Gagliardini, Roberta, Giacomelli, Andrea, Fiscon, Marta, Ferrara, Micol, Cervo, Adriana, Calza, Leonardo, Maggiolo, Franco, Rusconi, Stefano, Santoro, Maria Mercedes, Castagna, Antonella, and Spagnuolo, Vincenzo
- Subjects
- *
COHORT analysis , *DATA analysis , *RETROSPECTIVE studies , *HIV , *DRUGS - Published
- 2024
- Full Text
- View/download PDF
10. Persistent poor clinical outcomes of people living with HIV presenting with AIDS and late HIV diagnosis – results from the ICONA cohort in Italy, 2009-2022.
- Author
-
Mondi, Annalisa, Cozzi-Lepri, Alessandro, Tavelli, Alessandro, Cingolani, Antonella, Giacomelli, Andrea, Orofino, Giancarlo, De Girolamo, Gabriella, Pinnetti, Carmela, Gori, Andrea, Saracino, Annalisa, Bandera, Alessandra, Marchetti, Giulia, Girardi, Enrico, Mussini, Cristina, d'Arminio Monforte, Antonella, and Antinori, Andrea
- Subjects
- *
HIV-positive persons , *AIDS , *DELAYED diagnosis , *HIV infections , *HIV seroconversion , *TREATMENT effectiveness - Abstract
• A mortality gap remains for late presenters, particularly, AIDS presenters, in recent years. • Increased mortality for AIDS presenters was driven by AIDS events in the first year. • Two-year immune recovery is the key for long-term mortality in short-term AIDS survivors. • Late and AIDS presenters still show a higher risk treatment failure. • Urgent public health strategies are needed for emerging unknown HIV infections. Limited data are available on the long-term outcomes in recent years for late HIV diagnosis (LD). All subjects with HIV enrolled in the ICONA cohort in 2009-2022 who started antiretroviral treatment (ART) within 4 months from diagnosis were included and divided into: (i) pre-ART CD4 count ≥350/mm3 without AIDS (non-LD), (ii) pre-ART CD4 count <350/mm3 without AIDS (LD asymptomatic), and (iii) with AIDS events pre-ART (LD-AIDS). The estimated probability and independent risk for mortality (all-cause and cause-specific) and treatment failure were evaluated. Of 6813 participants (2448 non-LD, 3198 LD asymptomatic, and 1167 LD-AIDS), 161 (2.4%) died after ART initiation. At survival analysis, a higher probability of all-cause mortality has been identified for LD than non-LD (P <0.001) and within the former, for LD-AIDS over LD asymptomatic (P <0.001). After adjusting for confounders, LD showed a higher risk of all-cause mortality (vs non-LD adjusted hazard ratio (aHR) 5.51, P <0.001) and, in particular, being an AIDS presenter predicted a greater risk of all-cause (aHR = 4.42, P <0.001), AIDS-related (adjusted subhazard ratio [aSHR] = 16.86, P <0.001), and non-AIDS–related mortality (aSHR = 1.74, P = 0.022) than the rest of the late presenters. Among the short-term survivors in the LD-AIDS group, the long-term mortality was mediated by the lack of immune recovery at 2 years. Finally, LD compared with non-LD and, particularly, among the former, LD-AIDS over LD asymptomatic showed a greater risk of treatment failure. In recent years, LD subjects, particularly, AIDS presenters, remained at a higher risk of poorer outcomes. Public health strategies for early HIV diagnosis are urgently needed to constrain the mortality gap. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
11. Comparing the efficacy and safety of a first-line regimen with emtricitabine/tenofovir alafenamide fumarate plus either bictegravir or dolutegravir: Results from clinical practice.
- Author
-
Ciccullo, Arturo, Baldin, Gianmaria, Borghi, Vanni, Oreni, Letizia, Lagi, Filippo, Fusco, Paolo, Giacomelli, Andrea, Torti, Carlo, Sterrantino, Gaetana, Mussini, Cristina, Antinori, Spinello, and Di Giambenedetto, Simona
- Subjects
- *
DOLUTEGRAVIR , *TENOFOVIR , *HIV , *EMTRICITABINE , *HIV-positive persons - Abstract
• Both bictegravir (BIC) and dolutegravir (DTG), in association with emtricitabine/tenofovir alafenamide (FTC/TAF), show high efficacy in treatment-naïve people living with human immunodeficiency virus. • DTG+FTC/TAF discontinuations are mainly due to switching to a single tablet regimen or a two-drug regimen. • Favourable immunological recovery was observed, even in the short term. First-line integrase strand transfer inhibitor-based regimens have become commonly used in clinical practice over the last decade. This study aimed to analyse and compare the efficacy and safety of bictegravir (BIC) and dolutegravir (DTG) when prescribed in association with emtricitabine/tenofovir alafenamide (FTC/TAF) as part of a first-line regimen for the treatment of human immunodeficiency-1 (HIV-1) infection. Treatment-naïve people living with HIV (PLWHIV) starting a first-line regimen with either BIC/FTC/TAF (BIC group) or FTC/TAF+DTG (DTG group) were analysed. Snapshot analyses were performed after 24 and 48 weeks to evaluate virological efficacy. In addition, differences in the rate of treatment discontinuation (TD) between the two groups were evaluated using the Kaplan–Meier method and the log rank test. Data from 327 PLWHIV were analysed: 140 in the DTG group and 187 in the BIC group. At 48 weeks, 90.0% of individuals in the DTG group and 86.7% of those in the BIC group achieved HIV-RNA <50 copies/mL. In total, 88 and 38 cases of TD were observed in the DTG group and BIC group, respectively. The estimated probability of maintaining the study regimen at week 48 was 59.5% in the DTG group and 84.2% in the BIC group. Analysing changes in immunological parameters after 48 weeks, median improvements of +169 cell/mm3 (P <0.001) and +233 cell/mm3 (P <0.001) were observed in the DTG group and the BIC group, respectively. Both BIC and DTG, in combination with FTC/TAF, show promising efficacy and safety as first-line strategies in clinical practice, with favourable immunological recovery even in the short term. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
12. Characterization and outcomes of difficult-to-treat patients starting modern first-line ART regimens: Data from the ICONA cohort.
- Author
-
Gagliardini, Roberta, Tavelli, Alessandro, Rusconi, Stefano, Lo Caputo, Sergio, Spagnuolo, Vincenzo, Santoro, Maria Mercedes, Costantini, Andrea, Vergori, Alessandra, Maggiolo, Franco, Giacomelli, Andrea, Burastero, Giulia, Madeddu, Giordano, Quiros Roldan, Eugenia, d'Arminio Monforte, Antonella, Antinori, Andrea, and Cozzi-Lepri, Alessandro
- Subjects
- *
MODERN art , *TERMINATION of treatment , *TREATMENT failure , *BK virus , *ANTIRETROVIRAL agents , *VIRAL load - Abstract
• In PWH starting a modern ART regimen, estimated probability of becoming 'difficult to treat' due to multiple failures is 6.5% by 6 years. • Difficult to treat PWH had a significantly higher prevalence of AIDS diagnosis, were older and had lower nadir of CD4 compared to the non- difficult to treat PWH. • Difficult to treat PWH showed a higher risk of experiencing virological failure (aHR 2.23, 95% CI: 1.33–3.73), treatment failure (aHR 1.70, 95% CI: 1.03–2.78), and serious non-AIDS events/death (aHR 2.79, 95% CI: 1.18–6.61). Treatment failures to modern antiretroviral therapy (ART) raise concerns, as they could reduce future options. Evaluations of occurrence of multiple failures to modern ART are missing and their significance in the long run is unclear. People with HIV (PWH) in the ICONA cohort who started a modern first-line ART were defined as 'difficult to treat' (DTT) if they experienced ≥1 among: i) ≥2 VF (2 viral loads, VL>200 copies/mL or 1 VL>1000 copies/mL) with or without ART change; ii) ≥2 treatment discontinuations (TD) due to toxicity/intolerance/failure; iii) ≥1 VF followed by ART change plus ≥1 TD due to toxicity/intolerance/failure. A subgroup of the DTT participants were matched to PWH that, after the same time, were non-DTT. Treatment response, analysing VF, TD, treatment failure, AIDS/death, and SNAE (Serious non-AIDS event)/death, were compared. Survival analysis by KM curves and Cox regression models were employed. Among 8061 PWH, 320 (4%) became DTT. Estimates of becoming DTT was 6.5% (95% CI: 5.8–7.4%) by 6 years. DTT PWH were significantly older, with a higher prevalence of AIDS and lower CD4+ at nadir than the non-DTT. In the prospective analysis, DTT demonstrated a higher unadjusted risk for all the outcomes. Once controlled for confounders, significant associations were confirmed for VF (aHR 2.23, 1.33–3.73), treatment failure (aHR 1.70, 1.03–2.78), and SNAE/death (aHR 2.79, 1.18–6.61). A total of 6.5% of PWH satisfied our definition of DTT by 6 years from ART starting. This appears to be a more fragile group who may have higher risk of failure. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.